Related Experiment Video
Updated: Feb 14, 2026

Antimicrobial Characterization of Advanced Materials for Bioengineering Applications
Published on: August 4, 2018
Antimicrobial activity of a novel bioengineered honey against non-typeable Haemophilus influenzae biofilms: an in
Rachel S Newby1, Matthew Dryden2,3, Raymond N Allan1,4
1Clinical and Experimental Sciences, Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Abstract:
The opportunistic pathogen non-typeable Haemophilus influenzae (NTHi) plays an important role in many chronic respiratory diseases including otitis media, chronic rhinosinusitis, cystic fibrosis and chronic obstructive pulmonary disease. Biofilm formation has been implicated in NTHi colonisation, persistence of infection and recalcitrance towards antimicrobials. There is therefore a pressing need for the development of novel treatment strategies that are effective against NTHi biofilm-associated diseases. SurgihoneyRO is a honey-based product that has been bioengineered to enable the slow release of H2O2, a reactive oxygen species to which H. influenzae is susceptible. Treatment of established NTHi biofilms with SurgihoneyRO significantly reduced biofilm viability through enhanced H2O2 production and was shown to be more effective than the conventional antibiotic co-amoxiclav.
Insights
SurgihoneyRO, a novel honey-based treatment, effectively reduces non-typeable Haemophilus influenzae (NTHi) biofilms by releasing hydrogen peroxide. This innovative approach shows greater efficacy than co-amoxiclav for NTHi biofilm infections.
Area of Science:
- Microbiology and Infectious Diseases
- Biotechnology and Medical Devices
Background:
- Non-typeable Haemophilus influenzae (NTHi) is an opportunistic pathogen contributing to chronic respiratory diseases.
- NTHi biofilms promote persistent infections and antimicrobial resistance, necessitating new therapeutic strategies.
- Hydrogen peroxide (H2O2) exhibits susceptibility against H. influenzae.
Purpose of the Study:
- To evaluate the efficacy of SurgihoneyRO, a bioengineered honey product, against established NTHi biofilms.
- To investigate the mechanism of action involving slow release of H2O2.
Main Methods:
- Established NTHi biofilms were treated with SurgihoneyRO.
- Biofilm viability was assessed post-treatment.
- Comparison was made with the conventional antibiotic co-amoxiclav.
Main Results:
- SurgihoneyRO significantly reduced NTHi biofilm viability.
- Enhanced H2O2 production was observed as the primary mechanism.
- SurgihoneyRO demonstrated superior efficacy compared to co-amoxiclav.
Conclusions:
- SurgihoneyRO is a promising therapeutic agent for combating NTHi biofilm-associated respiratory infections.
- The slow release of H2O2 provides an effective strategy against recalcitrant NTHi biofilms.
Related Concept Videos
Antimicrobial Effectiveness
Biofilms
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

